We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) announced that the European Commission and regulatory authority in U.K. granted marketing approval for a new four-week, fixed-dose regimen of its PD-L1 inhibitor, Imfinzi in the approved indication of unresectable non-small cell lung cancer (NSCLC) after platinum-based chemoradiation therapy. Imfinzi is presently administered as a weight-based dosing of 10mg/kg every two weeks. The 1500 mg dosing regimen is available to patients weighing more than 30 kgs.
The four-week, fixed-dose regimen (1500 mg) will reduce patients’ medical visits by half, thereby improving patent convenience. The less-frequent dosing regimen becomes particularly important amid this pandemic as it will help avoid unnecessary risk of exposure to infection for lung cancer patients who are more vulnerable to complications from COVID-19.
The EU approval was expected in December as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended marketing authorization for the fixed-dose regimen of Imfinzi.
The new dosing regimen of Imfinzi was approved in the United States in November for approved indications of stage III NSCLC after chemoradiation therapy and previously-treated advanced bladder cancer.
In the past six months, AstraZeneca’s shares have lost 12.5% against an increase of 3.7% for the industry.
Imfinzi recorded sales of $148 billion in the first nine months of 2020, mainly driven by strong demand in lung cancer patients. Imfinzi is also being evaluated for multiple cancers, either alone or in combination with other regimens, including phase III trials in combination with tremelimumab in hepatocellular carcinoma (HCC, liver cancer), small cell lung cancer, metastatic urothelial cancer, head and neck squamous cell carcinoma (HNSCC) in earlier settings in NSCLC, among others
Other PD-L1 inhibitors on the market are Merck’s (MRK - Free Report) Keytruda, Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s Tecentriq and Pfizer’s (PFE - Free Report) Bavencio.
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing
AstraZeneca (AZN - Free Report) announced that the European Commission and regulatory authority in U.K. granted marketing approval for a new four-week, fixed-dose regimen of its PD-L1 inhibitor, Imfinzi in the approved indication of unresectable non-small cell lung cancer (NSCLC) after platinum-based chemoradiation therapy. Imfinzi is presently administered as a weight-based dosing of 10mg/kg every two weeks. The 1500 mg dosing regimen is available to patients weighing more than 30 kgs.
The four-week, fixed-dose regimen (1500 mg) will reduce patients’ medical visits by half, thereby improving patent convenience. The less-frequent dosing regimen becomes particularly important amid this pandemic as it will help avoid unnecessary risk of exposure to infection for lung cancer patients who are more vulnerable to complications from COVID-19.
The EU approval was expected in December as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended marketing authorization for the fixed-dose regimen of Imfinzi.
The new dosing regimen of Imfinzi was approved in the United States in November for approved indications of stage III NSCLC after chemoradiation therapy and previously-treated advanced bladder cancer.
In the past six months, AstraZeneca’s shares have lost 12.5% against an increase of 3.7% for the industry.
Imfinzi recorded sales of $148 billion in the first nine months of 2020, mainly driven by strong demand in lung cancer patients. Imfinzi is also being evaluated for multiple cancers, either alone or in combination with other regimens, including phase III trials in combination with tremelimumab in hepatocellular carcinoma (HCC, liver cancer), small cell lung cancer, metastatic urothelial cancer, head and neck squamous cell carcinoma (HNSCC) in earlier settings in NSCLC, among others
Other PD-L1 inhibitors on the market are Merck’s (MRK - Free Report) Keytruda, Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s Tecentriq and Pfizer’s (PFE - Free Report) Bavencio.
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>